Abstract
Aurora kinases play an important role in chromosome alignment, segregation, and cytokinesis during mitosis. We have recently shown that hematopoietic malignant cells including those from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) aberrantly expressed Aurora A and B kinases, and ZM447439, a potent inhibitor of Aurora kinases, effectively induced growth arrest and apoptosis of a variety of leukemia cells. The present study explored the effect of AZD1152, a highly selective inhibitor of Aurora B kinase, on various types of human leukemia cells. AZD1152 inhibited the proliferation of AML lines (HL-60, NB4, MOLM13), ALL line (PALL-2), biphenotypic leukemia (MV4-11), acute eosinophilic leukemia (EOL-1), and the blast crisis of chronic myeloid leukemia K562 cells with an IC50 ranging from 3 to 40 nM, as measured by thymidine uptake on day 2 of culture. These cells had 4N/8N DNA content followed by apoptosis, as measured by cell cycle analysis and annexin V staining, respectively. Of note, AZD1152 synergistically enhanced the anti-proliferative activity of vincristine, a tubulin depolymerizing agent, and daunorubicin, a topoisomerase II inhibitor, against the MOLM13 and PALL-2 cells in vitro. Furthermore, AZD1152 potentiated the action of vincristine and daunorubicin in a MOLM13 murine xenograft model. Taken together, AZD1152 is a promising new agent for treatment of individuals with leukemia. The combined administration of AZD1152 and conventional chemotherapeutic agent to patients with leukemia warrants further investigation.
Introduction
The Aurora family of serine/threonine kinases plays an important role in chromosome alignment, segregation and cytokinesis during mitosis. The family consists of three members: Aurora A, B and C, which share 67-76% amino acid sequence identity in their catalytic domains, but little similarities in their N-terminus. 1 Aurora A localizes to spindle poles and has a crucial role in bipolar spindle formation. 2 Aurora B is a chromosomal passenger protein and localizes at centromeres during prometaphase and subsequently relocates to midzone microtubules and midbodies during anaphase and telophase. 1, 3 Aurora B plays a role in chromosome alignment, kinetochore-microtubule biorientation, activation of the spindle assembly checkpoint and cytokinesis in association with phosphorylation of histone H3 on Ser 10. 1,3 Aurora C is specifically expressed in the testis and plays a role in spermatogenesis. 4 Its role in carcinogenesis remains unclear.
Previous studies found that Aurora A and B were aberrantly expressed in a variety of solid tumors including prostate, 5, 6 colon, 6 pancreas, 7 breast, 8 and thyroid cancers. 9 In addition, increased levels of Aurora kinases correlated with advanced clinical stage in individuals with prostate cancer, as well as, head and neck squamous cell carcinoma.
5,10
We have recently shown that hematological malignant cells including those from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), as well as chronic myeloid leukemia (CML) aberrantly expressed Aurora A and B kinases. 11 In addition, we have demonstrated that ZM447439, a novel and selective inhibitor of Aurora A and B kinases, effectively induced growth arrest and apoptosis of a variety of types of leukemia cells. 11 Recent studies performed by other groups noted that the phenotype of HeLa cells after their exposure to ZM447439 was similar to those induced by
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12
AZD1152 is a novel acetanilide-substituted pyrazole-aminoquinazoline prodrug that is converted rapidly to the active drug, AZD1152 hydroxy-QPA (AZD1152-HQPA), in human plasma. 13, 14 AZD1152-HQPA is a specific inhibitor of the enzymatic activity of Aurora kinase, with selectivity for Aurora B (IC50 of 0.37 nM versus 1368 nM for Aurora B and A kinases, respectively); the inhibitor had even less activity against a panel of greater than 50 other serine-threonine and tyrosine kinases including FLT3, JAK2, and Abl. 13, 14 Preliminary studies showed that AZD1152 was active against a variety of solid tumors including colon, breast, and lung cancers. 13, 14 However, the effect of AZD1152 in hematological malignancies remains to be fully elucidated. This study explored the effect of AZD1152 in a variety of types of leukemia, as well as test its ability to enhance the activity of conventional anti-cancer agents in vitro, as well as, in vivo. Reagents. AZD1152 and AZD1152-HQPA were provided by AstraZeneca (Macclesfield, United Kingdom). AZD1152-HQPA was dissolved in 100 % dimethyl sulfoxide (DMSO; Burdick & Jackson, Muskegon, MI) to a stock concentration of 10 mM and stored at -80°C. AZD1152 was dissolved in 3M Tris pH 9.0 at a concentration of 2.5 mg/ml and utilized for our in vivo studies.
Materials and Methods.

Cells.
Characteristics of the cell lines utilized in this study have been described. 15 Leukemia cells from patients, as well as, bone marrow mononuclear cells from healthy volunteers were freshly isolated as previously described.
15
Colony forming assay. 
Data analysis
The combination index (CI) for growth inhibition elicited by AZD1152-HPQA and vincristine in leukemia cells was calculated using the median effect method of Chou and For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From volunteers (n=3, data not shown) were more than 10 nM (data not shown).
AZD1152-HQPA blocked phosphorylation of histone H3 in leukemia cells. Histone H3 is one of the substrates of Aurora B kinase. 17 Phosphorylation of histone H3 on Ser10 is thought to play an important role in chromosome alignment during mitosis. 17 We, therefore, examined whether AZD1152-HQPA inhibited phosphorylation of histone H3 (Ser10) in leukemia cells using flow cytometry. Approximately 43 % or 52 % of the population of either MOLM13 or MV4-11 cells expressed the phosphorylated forms of histone H3; this population decreased to 25 % or 19 %, respectively, after their exposure to AZD1152-HQPA (10 nM) for 24 hrs (Fig. 1C) . Also, AZD1152 (3 μM, 3 hrs) significantly decreased expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells (Fig 1D; case # 8-10, Table 1 ), suggesting that AZD1152-HQPA effectively inhibited Aurora B kinase in these leukemia cells.
AZD1152-HQPA increased the population of cells with 4N/8N DNA content.
Exposure of MOLM13 and PALL2 cells to AZD1152-HQPA prominently increased cell 4N/8N DNA content in a dose-and time-dependent manner ( Fig. 2) , which was consistent with previous studies of ZM447439 (also an Aurora kinase inhibitor) in PALL-2 cells. 11 Our observations suggested that cells exposed to AZD1152-HQPA exited mitosis and subsequently proceeded through S phase in the absence of cytokinesis (cell division). For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From (synergistic anti-proliferative effect, Fig. 4B ). AZD1152-HQPA also synergistically enhanced the anti-proliferative activity of vincristine in MOLM13 cells (Figs. 4 C,D) .
AZD1152-
Moreover, AZD1152-HQPA synergistically increased the growth inhibitory activity of daunorubicin, a topoisomerase II inhibitor, against MOLM13 cells (Figs. 4 E,F) .
Furthermore, the effect on cleavage of PARP, a feature characteristic of apoptosis, was examined in PALL-2 or MOLM13 cells after exposure to AZD1152-HQPA and/or vincristine. Vincristine alone increased levels of the cleaved form of PARP in a dose-dependent manner in PALL-2 and MOLM13 cells (Figs. 4 G,H) . When the drug was combined with AZD1152-HQPA, the proportion of cleaved PARP was augmented (Figs. 4 G,H) . Likewise, AZD1152-HQPA enhanced the ability of daunorubicin to cleave PARP in MOLM13 cells (Fig. 4I) .
AZD1152 inhibited the proliferation of MOLM13 xenografts in vivo.
We evaluated the ability of AZD1152 to inhibit the growth of human MOLM13 cells growing as xenografts using an immunodeficient murine model. Tumor volumes were measured twice per week (Fig. 5A) , and tumor weights were determined at autopsy (Fig. 5B) . In addition, the difference of mean tumor weights between these two groups (78 ± 16 mg, AZD1152 treated; 583 ± 150 mg, control diluent) was significant (Fig. 5B, p<0.01) . None of the mice showed signs of wasting (Fig. 5C ) or other toxicity (data not shown). The tumors and organs of the mice were fixed, stained, and viewed by light microscopy. The tumors from control mice showed typical histological appearance of infiltrating leukemia cells (Fig. 5D ). Tumors from mice treated with AZD1152 showed necrotic tissue with infiltration of phagocytic cells (Fig. 5D) . No leukemia cells were detected. For (Fig. 6F) 
Discussions
This study found that AZD1152, a novel and selective Aurora B kinase inhibitor, slowed or prevented the growth of a variety of leukemia subtypes in vitro with IC50s ranging from 3 to 40 nM. IC50s of ZM334739, another Aurora kinase inhibitor, against these same leukemia cells ranged from 3 to 30 μM in our previous studies, 11 inhibitor entered and exited mitosis without cell division, and then proceeded to a second S phase. 12 On the other hand, vincristine inhibits mitosis; it binds to the beta-tubulin subunit of the alpha/beta-tubulin heterodimer, and inhibits polymerization of microtubules, resulting in failure of mitosis. 18 The mode of action in mitosis is different between each agent. This could explain the molecular mechanisms by which Both patients had relapsed after initial therapy with imatinib followed by allogenic bone marrow transplantation. In vitro experiments showed that freshly-isolated leukemia cells from these patients were resistant to growth inhibition after culture with imatinib (data not shown). AZD1152 may be useful for treatment of individuals with imatinib-resistant CML or ALL. Recent studies showed that the pan-Aurora kinase inhibitor MK-0457 (formerly VX-680) decreased the ABL-kinase activity induced by the T351I-BCR/ABL mutation, which mediates clinical resistance to imatinib, nilotinib, and dasatinib. 19 In addition, three patients with Ph+ ALL or CML possessing T315I BCR/ABL mutation achieved clinical responses after treatment with MK-0457. 
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